Mineralys Therapeutics news

The company is presenting late-breaking clinical data at a major medical conference, demonstrating continued progress in its lead drug candidate lorundrostat. The presentation of heart failure biomarker data suggests expanding therapeutic potential beyond hypertension, which could broaden the drug's market opportunity and support regulatory approval efforts.

The company eliminated future royalty obligations, securing $600 million in total capital ($100M debt at closing + $150M equity + $350M additional debt available), which strengthens its financial position and allows it to capture full value from lorundrostat sales. The transaction positions the company favorably for commercialization.

While the insider selling by Velan Capital could be viewed negatively, the stock has shown strong performance (87.84% YoY gain) and the company has substantial cash reserves ($646M) to support operations. The upcoming FDA decision on lorundrostat by December 2026 represents a significant catalyst. The insider reduction is modest relative to the company's potential, warranting a neutral stance rather than negative.

The company presented compelling clinical trial data showing statistically significant and clinically meaningful efficacy of lorundrostat in reducing blood pressure and albuminuria in CKD patients with hypertension. The drug demonstrated a favorable safety profile with low hyperkalemia rates. The positive data supports the FDA review process with an expected decision by December 2026, addressing a significant unmet medical need in a difficult-to-treat patient population.

Lorundrostat received FDA NDA acceptance with PDUFA target date of December 22, 2026, and demonstrated significant efficacy in Phase III trials for uncontrolled/resistant hypertension, positioning it as a leading novel conventional antihypertensive.